[go: up one dir, main page]

PE20021043A1 - DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2 - Google Patents

DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2

Info

Publication number
PE20021043A1
PE20021043A1 PE2002000197A PE2002000197A PE20021043A1 PE 20021043 A1 PE20021043 A1 PE 20021043A1 PE 2002000197 A PE2002000197 A PE 2002000197A PE 2002000197 A PE2002000197 A PE 2002000197A PE 20021043 A1 PE20021043 A1 PE 20021043A1
Authority
PE
Peru
Prior art keywords
pirazino
indol
tetrahydro
cycloalkyl
alkyl
Prior art date
Application number
PE2002000197A
Other languages
English (en)
Inventor
Paul Hebeisen
Patrizio Mattei
Taylor Sven
Hans Richter
Stephan Roever
Marc Muller
Original Assignee
Vernalis Res Ltd
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd, Hoffmann La Roche filed Critical Vernalis Res Ltd
Publication of PE20021043A1 publication Critical patent/PE20021043A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRAZINO-INDOL DE FORMULA I DONDE R1, R2, R3, R4 SON H, HALOGENO, HIDROXILO, ALQUILO, CICLOALQUILO, ARILALQUILO, ARILO, ALCOXILO, ALCOXIALQUILO, ENTRE OTROS; UNO DE R1, R2, R3, R4 NO ES H; R5 ES H, ALQUILO, CICLOALQUILO; R6 ES H, ALQUILO, CICLOALQUILO, HIDROXIALQUILO, ALCOXIALQUILO; R7 ES H, HALOGENO, ALQUILO, CICLOALQUILO, HIDROXIALQUILO, CARBOXIALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS (R)-6-TIENIL-4-METIL-1,2,3,4-TETRAHIDRO-PIRAZINO[1,2-a]INDOL; (R)-4,6-DIMETIL-1,2,3,4-TETRAHIDRO-PIRAZINO[1,2-a]INDOL; (R)-7-CLORO-4-METIL-1,2,3,4-TETRAHIDRO-PIRAZINO[1,2-a]INDOL, (R)-6-ETIL-4-METIL-1,2,3,4-TETRAHIDRO-PIRAZINO[1,2-a]INDOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y AL USO DEL COMPUESTO CON UN INHIBIDOR DE LIPASA COMO ORLISTAT. LOS COMPUESTOS SON AGONISTAS DEL RECEPTOR 5-HT2C Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE OBESIDAD, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, TRASTORNOS CARDIOVASCULARES, TROMBOSIS, DISFUNCION DE LA MOTILIDAD GASTROINTESTINAL, OBESIDAD, ENCEFALITIS, MENINGITIS
PE2002000197A 2001-03-13 2002-03-12 DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2 PE20021043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0106177.9A GB0106177D0 (en) 2001-03-13 2001-03-13 Piperazine derivatives

Publications (1)

Publication Number Publication Date
PE20021043A1 true PE20021043A1 (es) 2002-11-19

Family

ID=9910578

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000197A PE20021043A1 (es) 2001-03-13 2002-03-12 DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2

Country Status (20)

Country Link
US (1) US6844345B2 (es)
EP (1) EP1370561B1 (es)
JP (1) JP4230225B2 (es)
KR (1) KR100618748B1 (es)
CN (1) CN1245405C (es)
AR (1) AR035945A1 (es)
AT (1) ATE422498T1 (es)
AU (1) AU2002304833B2 (es)
BR (1) BR0208111A (es)
CA (1) CA2438596C (es)
DE (1) DE60231107D1 (es)
ES (1) ES2320739T3 (es)
GB (1) GB0106177D0 (es)
GT (1) GT200200048A (es)
MX (1) MXPA03008338A (es)
PA (1) PA8540801A1 (es)
PE (1) PE20021043A1 (es)
UY (1) UY27204A1 (es)
WO (1) WO2002072584A2 (es)
ZA (1) ZA200306613B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762132B1 (en) * 2000-08-31 2004-07-13 Micron Technology, Inc. Compositions for dissolution of low-K dielectric films, and methods of use
EA008148B1 (ru) 2002-06-19 2007-04-27 Биовитрум Аб Новые соединения, их применение и получение
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
EP1771413B1 (en) * 2004-05-03 2011-09-21 Janssen Pharmaceutica NV Benzofuran derivatives as selective androgen receptor modulators (sarms)
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
CN101312969A (zh) * 2005-11-18 2008-11-26 霍夫曼-拉罗奇有限公司 氮杂吲哚-2-甲酰胺衍生物
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US8207165B2 (en) 2008-03-28 2012-06-26 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
US20130143812A1 (en) * 2010-05-27 2013-06-06 Sekisui Medical Co., Ltd. Anti-inflammatory drug
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
HRP20161690T1 (hr) * 2012-03-16 2017-02-24 Vitae Pharmaceuticals, Inc. Modulatori jetrenog receptora x
JP6114814B2 (ja) 2012-03-16 2017-04-12 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 肝臓xレセプターモジュレーター
CN104540829B (zh) * 2012-08-06 2017-04-26 霍夫曼-拉罗奇有限公司 哌嗪并[1,2‑a]吲哚‑1‑酮和[1,4]二氮杂*并[1,2‑a]吲哚‑1‑酮
WO2014161801A1 (en) * 2013-04-02 2014-10-09 F. Hoffmann-La Roche Ag Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN106317058B (zh) * 2016-08-17 2018-10-02 广东省微生物研究所 化合物dichotocejpin A及其制备方法和在制备治疗糖尿病药物中的应用
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317524A (en) * 1965-02-04 1967-05-02 American Home Prod Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
WO1996012721A1 (en) * 1994-10-20 1996-05-02 American Home Products Corporation Indole derivatives useful as serotonergic agents
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE69916288T2 (de) 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende arzneimittel
PT1105122E (pt) 1998-08-14 2005-08-31 Hoffmann La Roche Composicoes farmaceuticas que contem inibidores de lipase
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
AU8395501A (en) * 2000-07-31 2002-02-13 Hoffmann La Roche Piperazine derivatives

Also Published As

Publication number Publication date
DE60231107D1 (de) 2009-03-26
AR035945A1 (es) 2004-07-28
KR100618748B1 (ko) 2006-08-31
CN1529706A (zh) 2004-09-15
MXPA03008338A (es) 2003-12-11
CA2438596A1 (en) 2002-09-19
JP4230225B2 (ja) 2009-02-25
US6844345B2 (en) 2005-01-18
ES2320739T3 (es) 2009-05-28
GT200200048A (es) 2002-11-15
CN1245405C (zh) 2006-03-15
WO2002072584A3 (en) 2003-01-03
ZA200306613B (en) 2004-11-25
WO2002072584A2 (en) 2002-09-19
PA8540801A1 (es) 2005-02-04
KR20030080255A (ko) 2003-10-11
UY27204A1 (es) 2002-09-30
GB0106177D0 (en) 2001-05-02
BR0208111A (pt) 2004-03-02
EP1370561A2 (en) 2003-12-17
JP2004532823A (ja) 2004-10-28
AU2002304833B2 (en) 2006-05-04
ATE422498T1 (de) 2009-02-15
CA2438596C (en) 2008-07-08
US20020169163A1 (en) 2002-11-14
EP1370561B1 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
PE20021043A1 (es) DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20081192A1 (es) Tratamiento del dolor
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
PE20010575A1 (es) Derivados de indol y su uso como ligandos del receptor 5ht2
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion
AR037222A1 (es) Un derivado de indol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y un procedimiento para preparar dicha composicion
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PE20040832A1 (es) Derivados de indolil pirazinona
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
UY28150A1 (es) Agentes terapeuticos
EA199900693A1 (ru) Атропизомеры 3-арил-4(3h)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов
PE20011030A1 (es) Combinaciones farmaceuticas que comprenden tegaserod y omeprazol
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
ATE356623T1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
PE20040763A1 (es) Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6
MXPA04000358A (es) Hexahidroazepino (4,5-g) indoles e indolinas como ligandos del receptor 5-ht.
AR056459A1 (es) Derivados de 3-sulfonililindazol para el tratamiento de trastornos del snc afectados por el receptor 5-ht6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal